Strongbridge

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of treatments for rare diseases with unmet needs. Strongbridge's first commercial product is KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. As of August 7, 2022, KEVEYIS holds orphan drug exclusivity in the United States. In addition to establishing this neuromuscular disease franchise, the company also has clinical-stage therapies for rare endocrine disorders. Strongbridge’s lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor being investigated for the treatment of endogenous Cushing's syndrome, and COR-005, a next-generation somatostatin analog (SSA) under investigation for the treatment of acromegaly.Strongbridge Biopharma Plc comprises two subsidiaries: Strongbridge Dublin Limited and Strongbridge U.S. Inc.